CYTOR and Duchenne muscular dystrophy: We chose to test CYTORexon2,ΨU RNA in myoblasts isolated from Duchenne muscular dystrophy (DMD) patients because these patients have impaired type II muscle fibers,[1, 2, 3] and we found ≈46% reduced CYTOR levels in myoblasts from DMD patients compared to myoblasts from healthy controls (Figure 3A).